Emcure Pharmaceuticals Consolidates Ownership of Gennova; Focuses on Biologics and Biosimilars
Pune, July 13, 2026 — Emcure Pharmaceuticals Limited announced it is acquiring full ownership of biopharma subsidiary Gennova Biopharmaceuticals Limited, as the company sharpens its strategic focus as a biologics and biosimilars entity. This consolidation comes alongside a leadership transition at Gennova to steer the next phase of growth in the specialized therapeutic area.Emcure is acquiring the entire 12.05% minority stake in Gennova that was held by Dr. Sanjay Singh and other shareholders, taking its ownership to 100%. With this acquisition, Emcure has made Gennova a wholly owned subsidiary.
Gennova will concentrate on its biologics franchise, including Elaxim®, TENECTASE®, Vintor®, Xgrast®/PEGEX®, and Hamsyl®. The company will leverage its established mammalian and microbial biomanufacturing platforms for biosimilars development and adjacent therapeutic platforms. Mr. Samit Mehta has been appointed to lead Gennova in this focused effort.
Commenting on the strategic move, Satish Mehta, Managing Director & CEO of Emcure Pharmaceuticals Limited, stated that the acquisition simplifies Gennova’s ownership structure. He thanked Dr. Sanjay Singh for his nearly two decades of scientific leadership at Gennova, noting that his stewardship built platforms and products crucial to Gennova's mission. Mr. Mehta added that positioning Gennova under Mr. Samit Mehta will drive its next phase of growth in biologics and biosimilars.
Mr. Samit Mehta, Whole Time Director & CEO of Gennova Biopharmaceuticals Limited, emphasized that Gennova will continue as a core anchor for the Group’s biologics and biosimilars capabilities within the "One Emcure framework." He noted that the work at Gennova will complement Emcure's broader R&D and pipeline priorities, maintaining a focus on execution, quality, and disciplined development across selected therapy areas.
The transaction is not anticipated to have a material impact on Emcure’s consolidated financials or its capital allocation framework. The company confirmed that its deleveraging trajectory, capital expenditure (capex) plans, and R&D investment plans remain unchanged.
About Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Ltd. (EPL) is an Indian pharmaceutical company based in Pune engaged in the development, manufacturing, and global marketing of various pharmaceutical products. Established in 1981, EPL is known for its commitment to innovation and quality. The R&D driven company operates in over 70 countries globally, including Europe and Canada. As of MAT March 2026, Emcure was ranked as the 13th largest pharma company in India based on Domestic Sales.EMCURE Stock Price Movement
Shares of Emcure Pharmaceuticals Limited today slipped by 1.40% in post-market trading, settling at ₹1793.30 after a subdued session. The stock traded within an intraday range spanning from ₹1785.50 to ₹1839, with 87,267 shares recorded in volume.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.